Development of a high-throughput perfused three dimensional cell culture platform for stem cell study and drug testing
Lead Research Organisation:
University of Oxford
Department Name: Engineering Science
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Zhanfeng Cui (Principal Investigator) |
Publications
Chawla R
(2014)
A polyhedral oligomeric silsesquioxane-based bilayered dermal scaffold seeded with adipose tissue-derived stem cells: in vitro assessment of biomechanical properties.
in The Journal of surgical research
Cui Z
(2013)
4th Annual Predictive Toxicology Summit 2012.
in Expert opinion on drug metabolism & toxicology
Kaul H
(2013)
A multi-paradigm modeling framework to simulate dynamic reciprocity in a bioreactor.
in PloS one
Li Z
(2013)
Development of in vitro 3D TissueFlex® islet model for diabetic drug efficacy testing.
in PloS one
Li Z
(2014)
Three-dimensional perfused cell culture.
in Biotechnology advances
Mouthuy PA
(2016)
Layering PLGA-based electrospun membranes and cell sheets for engineering cartilage-bone transition.
in Journal of tissue engineering and regenerative medicine
Wan X
(2016)
Three-dimensional perfused tumour spheroid model for anti-cancer drug screening.
in Biotechnology letters
| Description | Through the project, we improved two aspects related to microbioreactor technology - (i) increased throughput, so to increase productivity, (ii) introduced automation, to make the equipment more user friendly. Case studies using different cell platforms were published to show the efficacy. |
| Exploitation Route | Industry in Taiwan and China are exploring to commercialise the technology. |
| Sectors | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
| Description | A new drug testing platform based on advanced cell based assays was established and ready to be used in industry. The project also promoted collaboration between UK and Taiwan. |
| First Year Of Impact | 2014 |
| Sector | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Economic |
| Description | MeStar |
| Organisation | Oxford MeStar Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | I/my team are conducting research projects in translational and regenerative medicine, in particular developing enabling technologies for stem cell therapy. |
| Collaborator Contribution | My partner, Oxford MeStar Limited has contributed 90,000 pounds for research that develops enabling technologies for tissue engineering and stem cell therapy. This company has core technical expertise in bioprocessing, bioengineering and bio-manufacture. |
| Impact | PMID: 24184152 PMID: 23977329 PMID: 21976446 |
| Start Year | 2013 |